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Ischemic myelopathy and ANNPE are common neu-rologic emergencies in dogs that have similar clinical 
signs1–10 such as the hyperacute onset of nonprogressive, 
often markedly asymmetric spinal cord dysfunction with-
out obvious signs of pain.1,3,5,10 In dogs, ischemic myelop-
athy is most commonly associated with embolization of 
fibrocartilaginous material within the spinal cord vascu-
lature that is histologically indistinguishable from nucle-
us pulposus (ie, fibrocartilaginous embolism)5,6,11–13 and 
causes sudden onset of regional ischemia resulting in ne-
crosis of the spinal cord parenchyma.4–6,11–13 In contrast, 
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OBJECTIVE 
To compare clinical signs and outcomes between dogs with presumptive 
ischemic myelopathy and dogs with presumptive acute noncompressive 
nucleus pulposus extrusion (ANNPE). 
DESIGN
Retrospective study.
ANIMALS
51 dogs with ischemic myelopathy and 42 dogs with ANNPE examined at 1 
referral hospital.
PROCEDURES 
Medical records and MRI sequences were reviewed for dogs with a presump-
tive antemortem diagnosis of ischemic myelopathy or ANNPE. Information 
regarding signalment, clinical signs at initial examination, and short-term out-
come was retrospectively retrieved from patient records. Long-term out-
come information was obtained by telephone communication with referring 
or primary-care veterinarians and owners. 
RESULTS
Compared with the hospital population, English Staffordshire Bull Terriers 
and Border Collies were overrepresented in the ischemic myelopathy and 
ANNPE groups, respectively. Dogs with ANNPE were significantly older at 
disease onset and were more likely to have a history of vocalization at onset 
of clinical signs, have spinal hyperesthesia during initial examination, have a 
lesion at C1-C5 spinal cord segments, and be ambulatory at hospital dis-
charge, compared with dogs with ischemic myelopathy. Dogs with ischemic 
myelopathy were more likely to have a lesion at L4-S3 spinal cord segments 
and have long-term fecal incontinence, compared with dogs with ANNPE. 
However, long-term quality of life and outcome did not differ between dogs 
with ischemic myelopathy and dogs with ANNPE. 
CONCLUSIONS AND CLINICAL RELEVANCE 
Results revealed differences in clinical signs at initial examination between 
dogs with ischemic myelopathy and dogs with ANNPE that may aid clinicians 
in differentiating the 2 conditions. ( J Am Vet Med Assoc 2016;249:767–775)
ANNPE (previously referred to in the scientific litera-
ture as high velocity–low volume disk extrusion, type 
III disk extrusion, and traumatic intervertebral disk ex-
trusion) is suspected to cause a contusive rather than 
a primarily ischemic injury and occurs subsequent to 
trauma induced by explosive extrusion of normal non-
degenerate nucleus pulposus.2,8,14,15 Regardless of the 
condition (ischemic myelopathy or ANNPE), the clinical 
status of affected dogs typically stabilizes or improves 
within 24 hours after the onset of neurologic signs with-
out specific treatment.2–4, 10 The long-term outcome for 
both conditions is generally favorable, although the out-
come is less favorable for dogs that lose nociception in 
affected limbs, develop symmetric neurologic deficits, 
have a lesion affecting the spinal cord intumescences, 
or have specific MRI findings such as a lesion affecting a 
large area of the spinal cord.2–5 
ABBREVIATIONS
ANNPE Acute noncompressive nucleus pulposus extrusion
CI  Confidence interval
QOL Quality of life
SCS Spinal cord segment
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Definitive diagnosis of ischemic myelopathy or 
ANNPE requires histologic examination of the affected 
portion of the spinal cord or, for dogs with ANNPE, sur-
gical confirmation of extruded nucleus pulposus.4–6,8 
Because it is rare to definitively diagnose either condi-
tion prior to the death of the patient, both conditions 
are presumptively diagnosed on the basis of the pres-
ence of characteristic clinical findings in conjunction 
with established MRI criteria.1–3,7–9 
Although investigators of previous studies1,2,5,8,10 
have reported the characteristic clinical and diag-
nostic features of ischemic myelopathy and ANNPE 
separately, to our knowledge, no studies have been 
performed to compare the clinical signs and out-
comes between ischemic myelopathy and ANNPE. 
Identification of any differences in the clinical find-
ings and outcomes for these 2 conditions could be 
clinically relevant for attaining a presumptive ante-
mortem diagnosis and developing both short- and 
long-term prognoses. Therefore, the aims of the study 
reported here were to compare the clinical signs and 
outcomes between dogs with a presumptive ante-
mortem diagnosis of ischemic myelopathy and dogs 
with a presumptive antemortem diagnosis of ANNPE. 
We hypothesized that specific clinical variables could 
aid in differentiating between ischemic myelopathy 
and ANNPE and that, although short-term recovery 
may vary between the 2 conditions, they would have 
similar long-term outcomes. 
Materials and Methods
Animals
The study was approved by the Royal Veterinary 
College Ethics and Welfare Committee. Dogs exam-
ined at the University of London Royal Veterinary Col-
lege between November 2009 and December 2013 
because of acute onset of signs of spinal cord dys-
function that became nonprogressive 24 hours after 
onset were considered for study inclusion. Dogs were 
included in the study if a board-certified veterinary 
neurologist (SDD) and a board-certified veterinary 
radiologist (RD) agreed on a presumptive diagnosis 
of ischemic myelopathy or ANNPE following inde-
pendent review of available MRI sequences. Each in-
vestigator was unaware of (blinded to) the diagnosis 
on record for each dog when reviewing the MRI im-
ages. A presumptive diagnosis of ischemic myelopa-
thy or ANNPE was made on the basis of MRI criteria 
as described.1,2,7 Briefly, criteria for ANNPE included 
a focal intramedullary hyperintensity overlying an 
intervertebral disk space on T2-weighted images, re-
duction in nucleus pulposus volume, mild narrowing 
of an intervertebral disk space, and the presence of 
extraneous material or a change in signal intensity 
relative to that for normal epidural fat within the 
extradural space.2 Criteria for ischemic myelopathy 
included a focal intramedullary hyperintense lesion 
on T2-weighted images and the absence of the other 
criteria used to diagnose ANNPE. All MRI sequences 
were obtained with a 1.5-T unit.a Dogs were anesthe-
tized for the MRI evaluation. The anesthesia proto-
col used for each dog varied and was selected on the 
basis of the individual clinical requirements for each 
patient. T2-weighted and T1-weighted sequences 
were obtained in the sagittal and transverse planes 
for each dog. Postgadoliniumb T1-weighted, gradient 
echo, half Fourier acquisition single-shot turbo spin, 
and other MRI sequences were performed for some 
dogs at the request of the attending clinician. Dogs 
with concurrent spinal column disease (eg, vertebral 
fractures or Hansen type I disk disease) or that under-
went spinal decompression surgery were excluded 
from the study as were dogs for which the medical 
record was incomplete or the MRI sequences were 
incomplete or of inadequate quality for review. All 
dogs included in this study were included in a previ-
ous study16 that was conducted to evaluate inter- and 
intraobserver agreement in the differentiation of 
dogs with ischemic myelopathy from dogs with 
ANNPE by evaluation of MRI sequences.  
Medical records review
Information extracted from the medical record 
of each dog enrolled in the study included age, sex, 
breed, body weight, duration of clinical signs prior 
to examination, initiator of clinical signs (trauma, 
exercise, suspected exercise [dog was outside un-
observed in an open space], or unknown), whether 
the patient vocalized at onset of clinical signs (yes or 
no), progression history of clinical signs from onset 
to referral or examination, medications administered 
before referral or examination, and physical and neu-
rologic examination findings. During the initial ex-
amination and at the 4-week recheck examination, 
the severity of neurologic deficits (functional score) 
was assessed on a 5-point scale as described.1,2 Brief-
ly, for dogs with lesions from C1-T2, 0 = tetraplegia 
with absent nociception, 1 = tetraplegia with intact 
nociception, 2 = nonambulatory hemi- or tetraparesis 
with or without monoplegia, 3 = ambulatory hemi- or 
tetraparesis, and 4 = neurologically normal. For dogs 
with lesions from T3-S3, 0 = paraplegia with absent no-
ciception, 1 = paraplegia with intact nociception, 2 = 
nonambulatory mono- or paraparesis with or without 
monoplegia, 3 = ambulatory mono- or paraparesis, and 
4 = neurologically normal. 
Outcome and follow-up data collection
Information regarding short-term outcome was 
obtained from the medical record of each dog and in-
cluded duration of hospitalization, time from onset of 
clinical signs (time from onset) to first improvement 
in clinical condition, time from onset to voluntary 
urination, time from onset to independent ambula-
tion (if achieved), whether the patient was ambulato-
ry at discharge from the hospital (yes or no), and the 
functional score assigned at a recheck examination 4 
weeks after presumptive diagnosis. A minimum fol-
low-up period of 3 months was required for determi-
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nation of long-term outcome.17 Initially, the referring 
or primary-care veterinarian of each study dog was 
contacted by telephone for an interview. For dogs 
that were deceased, the date and cause of death were 
recorded as was the last documented neurologic sta-
tus. For dogs that were alive at the time of data collec-
tion, the owners were then contacted in accordance 
with local ethics and welfare committee guidelines 
to obtain follow-up information. Each owner was 
mailed a letter that outlined the study along with a 
standardized questionnaire prior to being contacted 
for a telephone interview. The questionnaire was ver-
bally administered during the telephone interview, 
and owners were asked to grade their dog’s current 
neurologic function (normal, strongly ambulatory 
with mild deficits, moderate to severe difficulty walk-
ing, or nonambulatory), urinary and fecal continence 
(fully continent, reduced continence, completely in-
continent), and QOL (scored on a linear scale from 
1 to 10 as described,18,19 where 1 = QOL “could not 
be worse” and 10 = QOL “could not be better”). The 
long-term outcome was defined as successful if a dog 
was clinically normal or had mild residual neurologic 
deficits but was able to maintain normal activities and 
had complete fecal and urinary continence.2 Long-
term outcome was defined as unsuccessful if a dog 
was euthanized because of a lack of clinical improve-
ment for at least 2 weeks or had marked neurologic 
deficits with or without complete urinary or fecal 
continence at the time of the telephone interview.2 
The same investigator (JF), who was blinded to the 
presumptive diagnosis of each dog, conducted all in-
terviews. The questionnaire was approved by the lo-
cal ethics and welfare committee.
Statistical analysis 
The data distribution for each continuous varia-
ble was assessed for normality by use of Shapiro-Wilk 
tests. Descriptive statistics were generated. The mean 
± SD was reported for continuous variables (body 
weight and age) that were normally distributed and 
the median (range) was reported for continuous vari-
ables that were not normally distributed and ordinal 
variables. The frequency and percentage was report-
ed for all categorical variables. Continuous variables 
were compared between dogs with ischemic my-
elopathy and dogs with ANNPE by use of independ-
ent-samples t tests for normally distributed data and 
Mann-Whitney U tests for nonnormally distributed 
data. For continuous variables that differed signifi-
cantly between dogs with ischemic myelopathy and 
dogs with ANNPE, a receiver operating characteristic 
curve was created to evaluate the ability of that vari-
able to discriminate between the 2 conditions. 
Categorical variables were compared between 
dogs with ischemic myelopathy and dogs with 
ANNPE by use of χ2 tests. For each binary variable that 
had a significant χ2 test result, the OR and associated 
95% CI were calculated to quantify the strength of 
the association. The respective associations between 
clinical and outcome variables and presumptive di-
agnosis were further assessed by multivariable logis-
tic regression. Separate multivariable models were 
created for clinical and outcome variables. Variables 
with values of P < 0.20 on univariate analysis were 
eligible for inclusion as fixed effects in those models. 
The dependent variable for the multivariable model 
for evaluation of clinical variables was the presence 
of ANNPE, whereas the dependent variable for the 
multivariable model for evaluation of outcome vari-
ables was the presence of ischemic myelopathy. The 
multivariable models were built in a stepwise manner 
with forward selection. Only variables with values of 
P < 0.05 were retained in the final models.
To assess potential breed predispositions to isch-
emic myelopathy and ANNPE, the hospital period 
prevalence (November 2009 to December 2013) of 
each condition within each breed represented in 
the study population was calculated (ie, number of 
dogs of a specific breed with ischemic myelopathy 
or ANNPE/number of dogs of that breed examined 
at the Royal Veterinary College Small Animal Refer-
ral Hospital) and compared with the hospital period 
prevalence of ischemic myelopathy and ANNPE in 
2 popular large-breed nonchondrodystrophic dog 
breeds (Boxer and German Shepherd Dog) without 
a known predisposition for either condition by the 
use of χ2 tests. All tests were 2 sided, and values of P 
< 0.05 were considered significant unless otherwise 
indicated. All analyses were performed with a com-
mercially available software program.c 
Results
Dogs
The MRI studies for 127 dogs were reviewed by 
the board-certified neurologist and radiologist, and 
they achieved a consensus diagnosis of ischemic my-
elopathy or ANNPE for 93 dogs. Thus, 93 dogs (51 
with a presumptive diagnosis of ischemic myelopathy 
and 42 with a presumptive diagnosis of ANNPE) were 
evaluated in this study. 
The 51 dogs with presumptive ischemic myelop-
athy included 21 neutered males, 11 sexually intact 
males, 14 neutered females, and 5 sexually intact fe-
males with a mean ± SD age of 5.9 ± 2.8 years and 
body weight of 23.3 ± 12.7 kg (51.3 ± 27.9 lb). Breeds 
represented included English Staffordshire Bull Ter-
rier (n = 11 [21.6%]), mixed (7 [13.7%]), Labrador Re-
triever (5 [9.8%]), Shih Tzu (3 [5.9%]), Bichon Frise 
(2 [3.9%]), Border Collie (2 [3.9%]), Golden Retriever 
(2 [3.9%]), Schnauzer (2 [3.9%]), Whippet (2 [3.9%]), 
and Belgian Sheepdog, Border Terrier, Bullmastiff, 
Dalmatian, Doberman Pinscher, English Bulldog, 
English Bull Terrier, English Springer Spaniel, Great 
Dane, Irish Wolfhound, Jack Russell Terrier, Lhasa 
Apso, Rottweiler, Siberian Husky, and Yorkshire Ter-
rier (1 [2.0%] each). The hospital period prevalence 
of ischemic myelopathy in English Staffordshire Bull 
Terriers (11/775 [1.4%]) and Whippets (2/134 [1.5%]) 
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was significantly greater than that for Boxers (0% 
[0/551]; P = 0.005) and German Shepherd Dogs (0% 
[0/733]; P = 0.001).
The 42 dogs with presumptive ANNPE included 
19 neutered males, 5 sexually intact males, 14 neu-
tered females, and 4 sexually intact females with a 
mean ± SD age of 7.0 ± 2.2 years and body weight 
of 22.4 ± 8.6 kg (49.3 ± 18.9 lb). Breeds represented 
included mixed (n = 9 [21.4%]), Labrador Retriever 
(8 [19.0%]), Border Collie (5 [11.9%]), English Staf-
fordshire Bull Terrier (4 [9.5%]), Whippet (4 [9.5%]), 
Lurcher (3 [7.1%]), Boxer (2 [4.8%]), Jack Russell Ter-
rier (2 [4.8%]), and Dalmatian, English Cocker Span-
iel, English Springer Spaniel, Greyhound, and Schnau-
zer (1 [2.4%] each). The hospital period prevalence 
of ANNPE in Whippets (4/134 [3%]) was significantly 
greater than that in Boxers (2/551 [0.4%]; P = 0.004) 
and German Shepherd Dogs (0/733 [0%]; P = 0.001). 
The hospital period prevalence of ANNPE in Border 
Collies (5/411 [1.2%]) was significantly greater than 
that in German Shepherd Dogs (P = 0.003).
Univariate results for comparisons of signalment 
and clinical variables between dogs with ischemic 
myelopathy and dogs with ANNPE were summarized 
(Table 1). Although the results of the overall χ2 anal-
ysis suggested that breed distribution did not differ 
significantly (P = 0.223) between dogs with ischemic 
myelopathy and dogs with ANNPE, results of post 
hoc χ2 tests indicated that the ischemic myelopathy 
group contained significantly more English Stafford-
shire Bull Terriers than Border Collies (P = 0.047) or 
sighthounds (Greyhounds and Whippets; P = 0.047), 
compared with the ANNPE group. Although Labrador 
Retriever was one of the most commonly represented 
breeds in both the ischemic myelopathy and ANNPE 
groups, it was also one of the most commonly repre-
sented breeds in the overall hospital population dur-
ing the study period, and the hospital period preva-
lences for ischemic myelopathy (5/1,838 [0.3%]) and 
ANNPE (8/1,838 [0.4%]) in Labrador Retrievers did 
not differ significantly from those for the 2 control 
breeds (Boxer and German Shepherd Dog). 
The sex distribution (P = 0.583) and mean body 
weight (P = 0.706) did not differ significantly be-
tween dogs with ischemic myelopathy and dogs with 
ANNPE. The mean age for dogs with ANNPE was sig-
nificantly (P = 0.033) greater than that for dogs with 
ischemic myelopathy. However, the area under the re-
ceiver operating characteristic curve was only 0.652, 
which suggested that the discriminatory ability of 
age to distinguish dogs with ischemic myelopathy 
from those with ANNPE was poor. 
Clinical signs
Dogs that vocalized at the onset of clinical signs 
were approximately 2.5 times (OR, 2.52; 95% CI, 1.09 
to 5.83; P = 0.029) as likely to have ANNPE, com-
pared with dogs that did not vocalize at the onset of 
clinical signs. Similarly, dogs with spinal hyperesthe-
sia during the initial neurologic examination were ap-
proximately 3.0 times (OR, 2.96; 95% CI, 1.22 to 7.17; 
P = 0.015) as likely to have ANNPE, compared with 
dogs that did not have spinal hyperesthesia during 
the initial neurologic examination. Of 19 dogs that 
vocalized at the onset of clinical signs and had spinal 
hyperesthesia during the initial neurologic examina-
tion, 15 had a presumptive diagnosis of ANNPE; thus, 
dogs that vocalized at the onset of clinical signs and 
had spinal hyperesthesia during the initial neurologic 
examination were approximately 6.5 times (OR, 6.53; 
95% CI, 1.97 to 21.68; P = 0.001) as likely to have 
ANNPE, compared with dogs that did not vocalize 
at the onset of clinical signs and did not have spinal 
hyperesthesia during the initial neurologic examina-
tion. Clinical variables eligible for inclusion in the 
multivariable model included age, vocalization at 
onset of clinical signs, location of spinal cord lesion, 
and presence of spinal hyperesthesia during the ini-
tial neurologic examination. The final multivariable 
logistic regression model included only vocalization 
at onset of clinical signs.
Short- and long-term outcomes
Five of the 93 (5.4%) study dogs were euthanized 
at the time of presumptive diagnosis because of a 
poor prognosis, and 2 (2.2%) dogs were euthanized 
after 6 and 12 days of hospitalization because their 
clinical condition had failed to improve. Those 7 dogs 
(5 with ischemic myelopathy and 2 with ANNPE) 
were not included in any of the subsequent outcome 
analyses. Duration of hospitalization (P = 0.900), time 
from onset to first improvement (P = 0.538), and time 
from onset to independent urination (P = 0.217) did 
not differ significantly between dogs with ischemic 
myelopathy and dogs with ANNPE (Table 2). Dogs 
with ANNPE were approximately 2.9 times (OR, 2.88; 
95% CI, 1.17 to 7.10; P = 0.020) as likely to be ambula-
tory at hospital discharge, compared with dogs with 
ischemic myelopathy. A recheck examination was 
performed 4 weeks after presumptive diagnosis for 
31 dogs (14 with ischemic myelopathy and 17 with 
ANNPE). During those examinations, 1 dog with 
ANNPE had a functional score of 0 (had paraplegia 
with absent nociception), 2 dogs with ischemic my-
elopathy and 1 dog with ANNPE had a functional score 
of 2 (were nonambulatory with intact nociception), 
11 dogs with ischemic myelopathy and 13 dogs with 
ANNPE had a functional score of 3 (were ambulato-
ry with minor neurologic deficits), and 1 dog with 
ischemic myelopathy and 2 dogs with ANNPE had 
a functional score of 4 (neurologically normal). 
The functional score assigned during the recheck 
examination did not differ significantly (P = 0.669) 
between dogs with ischemic myelopathy and dogs 
with ANNPE.  
Information regarding long-term outcome was 
available for 80 (43 dogs with ischemic myelopathy 
and 37 dogs with ANNPE) of the 93 (86%) study 
dogs; it was not available for the 7 dogs that were eu-
thanized within 12 days after presumptive diagnosis 
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and an additional 6 dogs that were lost to follow-up. 
Long-term follow-up information was obtained from 
the referring veterinarian (n = 27 dogs) or owner 
(53 dogs) at a median of 730 days (range, 71 to 1,676 
days) after presumptive diagnosis. The proportion of 
dogs with a successful long-term outcome did not dif-
fer significantly (P = 0.167) between dogs with isch-
emic myelopathy and dogs with ANNPE (Table 2), 
and this result was consistent even when the 7 dogs 
that were euthanized within 12 days after presump-
tive diagnosis were included in the analysis. Of the 
80 dogs for which long-term follow-up information 
was obtained, the outcome was considered success-
ful for 59 (73.8%) and unsuccessful for 21 (26.2%). 
Thirty-five of the 59 dogs with a successful outcome 
had recovered normal neurologic function, whereas 
the remaining 24 dogs had minor neurologic deficits 
but had complete urinary and fecal continence. Of 
the 21 dogs that had an unsuccessful outcome, 1 was 
euthanized 257 days after presumptive diagnosis be-
 Dogs with  
 ischemic  Dogs with
Variable myelopathy ANNPE P value
Sex    
   Male 32 (62.7) 24 (57.1) 0.583
   Female 19 (37.3) 18 (42.9) 
Age 5.9 ± 2.8 7.0 ± 2.2 0.033
Body weight 23.3 ± 12.7 22.4 ± 8.6 0.706
Duration of clinical signs before examination (d) 0 (0–6) 0 (0–3) 0.894
Initiator of clinical signs   
   Exercise 31 (60.8) 27 (64.3) 0.391
   Trauma 2 (3.9) 5 (11.9) 
   Suspected exercise (dog outside unobserved) 9 (17.6) 5 (11.9) 
   Unknown 9 (17.6) 5 (11.9) 
Vocalization at onset of clinical signs   
   Yes 20 (39.2) 26 (61.9) 0.029
   No 31 (60.8) 16 (38.1) 
Progression of clinical signs   
   Stable 40 (78.4) 29 (69.0) 0.579
   Improved 9 (17.6) 11 (26.2) 
   Deteriorated 2 (3.9) 2 (4.8) 
Medication received before referral examination   
   None 29 (56.9) 24 (57.1) 0.740
   NSAID 18 (35.3) 14 (33.3) 
   Corticosteroid 4 (7.8) 4 (9.5) 
SCS where lesion was located   
   C1-C5  0 (0.0) 7 (16.7) 0.005
   C6-T2 7 (13.7) 8 (19.0) 
   T3-L3 21 (41.2) 11 (26.2) 
   L4-S3 6 (11.8) 0 (0.0) 
   T3-L3 with suspected spinal shock 17 (33.3) 16 (38.1) 
Symmetry of neurologic deficits   
   Symmetric 8 (15.7) 4 (9.5) 0.609
   Left lateralized 25 (49.0) 24 (57.1) 
   Right lateralized 18 (35.3) 14 (33.3) 
Spinal hyperesthesia   
   Yes 12 (23.5) 20 (47.6) 0.015
   No 39 (76.5) 22 (52.4) 
Neurologic functional score*   
   0 4 (7.8) 3 (7.1) 0.590
   1  7 (13.7) 7 (16.7) 
   2  25 (49.0) 15 (35.7) 
   3 15 (29.4) 17 (40.5) 
Values represent number (%) of dogs, mean ± SD, or median (range) unless otherwise specified. The 
presumptive diagnosis for each dog was made on the basis of consensus between a board-certified veterinary 
neurologist and radiologist following independent review of available MRI sequences. 
*Scored on a 5-point scale; for dogs with lesions from C1-T2, 0 = tetraplegia with absent nociception, 1 = 
tetraplegia with intact nociception, 2 = nonambulatory hemi- or tetraparesis with or without monoplegia, 3 = 
ambulatory hemi- or tetraparesis, and 4 = neurologically normal. For dogs with lesions from T3-S3, 0 = paraplegia 
with absent nociception, 1 = paraplegia with intact nociception, 2 = nonambulatory mono- or paraparesis with 
or without monoplegia, 3 = ambulatory mono- or paraparesis, and 4 = neurologically normal. None of the dogs 
had a functional score of 4 at initial examination. Values of P < 0.05 were considered significant.
Table 1—Comparison of signalment and initial clinical variables between 51 dogs with 
presumptive ischemic myelopathy and 42 dogs with presumptive ANNPE.
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cause of recurrence of clinical signs, 4 had partial 
urinary and fecal incontinence, 6 had partial urinary 
incontinence only, 6 had partial fecal incontinence 
only, 3 had partial urinary incontinence and com-
plete fecal incontinence, and 1 dog had severe neu-
rologic deficits that prevented it from independently 
performing normal daily tasks despite the fact that 
it had complete urinary and fecal continence. The 
proportion of dogs with long-term fecal incontinence 
in the ischemic myelopathy group (n = 11 dogs) was 
significantly (P = 0.016) greater than that for the 
ANNPE group (2 dogs), with dogs with ischemic my-
elopathy being approximately 8.3 times (OR, 8.25; 
95% CI, 1.61 to 42.28; P = 0.005) as likely as dogs with 
ANNPE to have partial or complete fecal incontinence 
at long-term follow-up. Outcome variables eligible for 
inclusion in the multivariable model included ambu-
latory at hospital discharge, number of months to 
maximum improvement, long-term fecal continence, 
and outcome (successful or unsuccessful). The final 
multivariable logistic regression model included only 
long-term fecal continence. For the 53 dogs for which 
long-term follow-up information was obtained from 
the owner, the median owner-perceived QOL score 
was 8 (range, 5 to 10), and all owners believed that 
their dogs had an acceptable QOL. 
Discussion
Results of the present study identified several 
differences in the clinical and short- and long-term 
outcomes between dogs with presumptive ischemic 
myelopathy and dogs with presumptive ANNPE. Com-
pared with dogs with ischemic myelopathy, dogs with 
ANNPE were older at the time of presumptive diagno-
sis, more likely to have spinal hyperesthesia during 
the initial neurologic examination, and more likely 
to be ambulatory at hospital discharge. Although the 
long-term success rate did not differ significantly be-
tween dogs with ischemic myelopathy and dogs with 
 Dogs with 
 ischemic  Dogs with 
Variable myelopathy ANNPE P value
Duration of hospitalization (d) 3 (1–18) 3 (0–58) 0.900
Time from onset to first improvement (d) 1 (0–15) 1.5 (0–10) 0.538
Time from onset to independent urination (d) 1 (0–14) 1 (0–14) 0.217
Ambulatory at discharge   
   Yes 22 (47.8) 29 (72.5) 0.020
   No 24 (52.2) 11 (27.5) 
Time from onset to independent ambulation (d) 1 (0–84) 2 (0–84) 0.629
Time from onset to maximum clinical 3 (1–48) 2 (0–48) 0.122
   improvement (mo)*
Long-term neurologic function*   
   Normal 4 (14.8) 5 (19.2) 0.853
   Mild deficits 20 (74.1) 19 (73.1) 
   Moderate or marked deficits (patient ambulatory) 3 (11.1) 2 (7.7) 
   Severe deficits (patient not ambulatory) 0 (0.0) 0 (0.0) 
Long-term urinary continence*   
   Normal 19 (70.4) 21 (80.8) 0.379
   Incomplete or intermittent 8 (29.6) 5 (19.2) 
   Completely incontinent 0 (0.0) 0 (0.0) 
Long-term fecal continence*   
   Normal 16 (59.3) 24 (92.3) 0.016
   Incomplete or intermittent 9 (33.3) 1 (3.8) 
   Completely incontinent 2 (7.4) 1 (3.8) 
Owner-perceived QOL score*† 8 (5–10) 8.3 (5–10) 0.303
Long-term outcome‡   
   Successful 29 (67.4) 30 (81.1) 0.167
   Unsuccessful 14 (32.6) 7 (18.9) 
*Results reported only for the 27 dogs with ischemic myelopathy and 26 dogs with ANNPE for which follow-
up information was obtained via a telephone interview with the owner at least 3 months after the presumptive 
diagnosis was made. †Scored on a subjective scale of 1 to 10, where 1 = QOL “could not be worse” and 10 = 
QOL “could not be better.” ‡Long-term outcome was defined as successful if a dog was clinically normal or had 
mild residual neurologic deficits but was able to maintain normal activities and had complete fecal and urinary 
continence and unsuccessful if a dog was euthanized because of a lack of clinical improvement for at least 2 
weeks or had marked neurologic deficits with or without complete urinary or fecal continence at the time of 
the telephone interview. 
See Table 1 for remainder of key.
Table 2—Comparison of short- and long-term outcomes for the dogs of Table 1.
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ANNPE, dogs with ischemic myelopathy were more 
likely to have long-term fecal incontinence. Those dif-
ferences may have important clinical and prognostic 
implications.  
As in previous studies,1–5,8,10 most dogs with isch-
emic myelopathy or ANNPE evaluated in the present 
study had a hyperacute onset of clinical signs, which 
was often associated with strenuous exercise or per-
ceived trauma. The clinical signs for the dogs of this 
study were frequently lateralized and generally be-
came nonprogressive 24 hours after onset. The dis-
tributions for age at onset for dogs with ischemic my-
elopathy and ANNPE were likewise similar to those 
reported in other studies.2,8,10 The fact that dogs with 
ANNPE tended to be older than dogs with ischemic 
myelopathy may be associated with differences in 
the pathogenesis of the 2 conditions. Age-related 
changes in the microstructure and biomechanics of 
the anulus fibrosus including alterations in collagen 
fiber cross-linking, decreases in water and proteo-
glycan content, and changes in interfiber cohesive-
ness have been reported in sheep,20 humans,21 and 
dogs.22 Those changes might increase the likelihood 
for separation of annular fibers and the development 
of annular clefts, which provide potential pathways 
for extrusion of nuclear material when mechanical 
stress is applied to the spinal column.20 Additionally, 
in dogs, the strength of intervertebral disks decreases 
with age.22 Those factors collectively suggest that the 
risk of ANNPE may increase with age. 
In the present study, dogs in both the ischemic 
myelopathy and ANNPE groups tended to be rep-
resentative of large nonchondrodystophic breeds, 
which was consistent with dogs with ischemic mye-
lopathy and ANNPE evaluated in other studies.1,2,4,5,10 
However, results of the present study suggested cer-
tain predispositions for ischemic myelopathy and 
ANNPE. Compared with the general population of 
dogs examined at the hospital during the observa-
tion period, English Staffordshire Bull Terriers and 
Whippets were overrepresented in the ischemic my-
elopathy group and Border Collies and sighthounds 
(Greyhounds and Whippets) were overrepresented 
in the ANNPE group. Although the underlying reason 
for those apparent predispositions is unknown, it is 
noteworthy that these 4 breeds represent very active 
and athletic dogs. 
Dogs of the present study with ANNPE were 
significantly more likely to vocalize at the onset of 
clinical signs and more frequently had spinal hyper-
esthesia during the initial neurologic examination, 
compared with dogs with ischemic myelopathy. That 
finding was consistent with the results of another 
study4 and suggested that the presence of a focal area 
of spinal hyperesthesia might be useful for distin-
guishing dogs with ANNPE from dogs with ischemic 
myelopathy. The proposed etiology for ANNPE is an 
explosive extrusion of nondegenerate nucleus pulp-
osus material into the spinal canal,2,8,9,15 potentially 
causing pain secondary to trauma to the overlying 
meninges of the spinal cord, periosteum, or dorsal 
longitudinal ligament, resulting in a focal area of spi-
nal hyperesthesia. 
 Although most dogs of the present study had le-
sions localized to the T3-L3 SCSs, the proportion of 
dogs with lesions affecting the C1-C5 SCSs was sig-
nificantly greater for the ANNPE group than for the 
ischemic myelopathy group, whereas the proportion 
of dogs with lesions affecting the L4-S3 SCSs was sig-
nificantly greater for the ischemic myelopathy group 
than for the ANNPE group. In fact, in this study, none 
of the dogs with ANNPE had lesions affecting the 
L4-S3 SCSs, and none of the dogs with ischemic my-
elopathy had lesions affecting the C1-C5 SCSs. Results 
of other studies1,5–7 involving dogs with presumptive 
or confirmed ischemic myelopathy also indicate that 
the incidence of C1-C5 lesions is low, and most sug-
gest that lesions predominantly occur at the T3-L3 
and L4-S3 SCSs. In the present study, dogs with de-
creased spinal reflexes in the pelvic limbs were di-
vided into 2 groups (those with L4-S3 myelopathy and 
those with T3-L3 myelopathy and suspected spinal 
shock23) by assessment of withdrawal reflexes, myo-
tatic reflexes, muscle tone, and the cutaneous trunci 
reflex. Following that categorization, the L4-S3 my-
elopathy group contained more dogs with ischemic 
myelopathy than dogs with ANNPE, a finding that 
was consistent with the results of other studies.1,2,5,6 
In the present study, all dogs with ANNPE had lesions 
in either the cervical or thoracolumbar portion of 
the vertebral column, which was consistent with the 
portions of the vertebral column that are predisposed 
to intervertebral disk herniation (Hansen type I disk 
disease), fractures, and luxations.8,9,24–26 It has been 
hypothesized that variations in biomechanical forces 
on the vertebral column at the junctions between the 
fairly static thoracic portion and the more dynamic 
cervical and thoracolumbar portions are responsible 
for the predilection sites for ANNPE.2,9 
Dogs with ANNPE were significantly more likely 
than dogs with ischemic myelopathy to be ambula-
tory at hospital discharge, even though the functional 
score at initial examination, duration of hospitaliza-
tion, overall long-term outcome, and time from onset 
to regaining independent ambulation and urination 
and maximum clinical improvement did not differ 
significantly between the 2 groups. Ischemic myelop-
athy is characterized by complete loss of the blood 
supply to a focal area of the spinal cord, whereas 
ANNPE lesions are variable and contusive in nature; 
therefore, recovery of neurologic function may be 
faster for dogs with ANNPE than for dogs with isch-
emic myelopathy.4–6,27 
In dogs, both ischemic myelopathy and ANNPE 
are associated with a risk of fecal incontinence.1,2,10 
Results of the present study suggested that dogs with 
ischemic myelopathy were more likely to have long-
term fecal incontinence than were dogs with AN-
NPE. The presence of a lower motor neuron lesion at 
L4-S3 was not associated with an increased risk of fe-
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cal incontinence in the present study. In fact, 12 of the 
13 dogs with long-term fecal incontinence had a spi-
nal cord lesion at T3-L3. This finding was consistent 
with the results of other studies that involved dogs2,24 
and human patients28 in which upper motor neuron 
lesions were associated with a long-term reduction 
in fecal continence because of impaired perception 
of rectal distension, loss of inhibitory upper motor 
neuron pathways to rectal reflexes, and reduced vol-
untary control of the external anal sphincter. Those 
types of deficits may be more likely to develop with 
ischemic myelopathy because ischemic lesions typi-
cally affect the central and dorsal portions of the 
spinal cord, potentially damaging the rectal sensory 
tracts, whereas ANNPE lesions generally cause contu-
sive damage to the ventral or lateral portions of the 
spinal cord. 
Overall, most owners of the dogs of the present 
study perceived that the long-term QOL for their pets 
was good, even though some dogs continued to have 
a reduction in fecal continence. Owner-perceived 
QOL is an admittedly subjective measure and prone 
to bias. Consequently, it was not surprising that the 
clinical status (ie, long-term neurologic function and 
extent of urinary and fecal continence) varied among 
dogs that were assigned the same QOL score. Unfor-
tunately, a gold standard for assessing QOL in com-
panion animals has yet to be established.29 Regard-
less, results of the present study indicated that the 
owner-perceived long-term QOL did not differ sig-
nificantly between dogs with ischemic myelopathy 
and dogs with ANNPE.  It is possible that the clinical 
status of the 7 dogs that were euthanized within 2 
weeks after the presumptive diagnosis and excluded 
from the outcome analysis might have improved had 
they not been euthanized. However, it is unlikely that 
those dogs would have had a successful outcome, and 
when the analysis for long-term outcome was repeat-
ed with those dogs included and coded as unsuccess-
ful outcomes, the results did not change. 
The main limitation of the present study was 
that, because of its retrospective nature, patient as-
sessments could not be standardized. Also, dogs were 
required to have only a presumptive, and not a defini-
tive (postmortem), diagnosis of ischemic myelopathy 
or ANNPE for study enrollment. Inclusion of only 
dogs with a confirmed postmortem diagnosis of isch-
emic myelopathy or ANNPE would likely have biased 
the study population toward more severely affected 
patients, which in turn would have strongly affected 
the outcome results. The presumptive diagnosis for 
each dog of this study was made on the basis of con-
sensus between a board-certified neurologist and ra-
diologist following independent review of available 
MRI sequences; therefore, we have a high level of 
confidence that the presumptive diagnosis was cor-
rect for most dogs. 
Findings of the present study indicated that dogs 
with ANNPE were generally older at disease onset and 
more likely to have spinal hyperesthesia during the 
initial examination, compared with dogs with isch-
emic myelopathy. Although dogs with ANNPE were 
more likely to be ambulatory at hospital discharge 
(which suggested a quicker improvement in initial 
neurologic signs) than were dogs with ischemic my-
elopathy, the long-term outcome and QOL were good 
for dogs with either condition, provided that nocicep-
tion was intact. Dogs with ischemic myelopathy were 
more likely to develop long-term fecal incontinence 
than were dogs with ANNPE. These findings can be 
used by clinicians as supporting data when discuss-
ing a presumptive diagnosis of ischemic myelopathy 
or ANNPE with owners and advising them of the po-
tential prognosis and long-term outcomes. 
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From this month’s AJVR 
Efficacy of intravenous administration of hyaluronan,  
sodium chondroitin sulfate, and N-acetyl-d-glucosamine  
for prevention or treatment of osteoarthritis in horses
David D. Frisbie et al
OBJECTIVE
To evaluate the efficacy of IV administration of a product containing hyaluronan, sodium chondroitin 
sulfate, and N-acetyl-d-glucosamine for prevention or treatment of osteoarthritis in horses.
ANIMALS
32 healthy 2- to 5-year-old horses. 
PROCEDURES
The study involved 2 portions. To evaluate prophylactic efficacy of the test product, horses received 
5 mL of the product (n = 8) or saline (0.9% NaCl) solution (8; placebo) IV every fifth day, starting on 
day 0 (when osteoarthritis was induced in the middle carpal joint of 1 forelimb) and ending on day 
70. To evaluate treatment efficacy, horses received either the product or placebo (n = 8/treatment) 
on days 16, 23, 30, 37, and 44 after osteoarthritis induction. Clinical, diagnostic imaging, synovial fluid, 
gross anatomic, and histologic evaluations and other tests were performed. Results of each study 
portion were compared between treatment groups.
RESULTS
Limb flexion and radiographic findings were significantly worse for horses that received test product 
in the prophylactic efficacy portion than for placebo-treated horses or product-treated horses in the 
treatment efficacy portion. In the prophylactic efficacy portion, significantly less articular cartilage 
erosion was identified in product-treated versus placebo-treated horses. In the treatment efficacy 
portion, joints of product-treated horses had a greater degree of bone edema identified via MRI than 
did placebo-treated horses but fewer microscopic articular cartilage abnormalities. 
CONCLUSIONS AND CLINICAL RELEVANCE
Results suggested that caution should be used when administering the evaluated product IV to 
horses, particularly when administering it prophylactically, as it may have no benefit or may even 
cause harm. (Am J Vet Res 2016;77:1064–1070)
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